Checkpoint Therapeutics Stock
Checkpoint Therapeutics Stock
The community is currently still undecided about Checkpoint Therapeutics with 2 Buy predictions and 0 Sell predictions.
With a target price of 4 € there is potential for a 698.08% increase which would mean more than doubling the current price of 0.5 € for Checkpoint Therapeutics.
Pros and Cons of Checkpoint Therapeutics in the next few years
Pros
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Checkpoint Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Checkpoint Therapeutics | - | - | - | - | - | - | - |
| Evolus Inc | -1.030% | -2.488% | -31.228% | -68.387% | -28.073% | -54.943% | -32.062% |
| Madrigal Pharmaceuticals inc. | 0.440% | -2.478% | -20.028% | 30.322% | -18.696% | 53.523% | 338.067% |
| Heron Therapeutics Inc. | -1.610% | -2.732% | 8.796% | -32.780% | 5.476% | -55.416% | -92.833% |
Comments
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $4.80 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $4.80 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) is now covered by analysts at D. Boral Capital. They set a "buy" rating and a $9.00 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat